Seelos Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SEEL research report →
Companyseelostherapeutics.com
Seelos Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD).
- CEO
- Raj Mehra
- IPO
- 1999
- Employees
- 8
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $214.97K
- P/E
- -0.05
- P/S
- 0.10
- P/B
- -0.05
- EV/EBITDA
- -0.30
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -1267.09%
- Op Margin
- -1838.36%
- Net Margin
- -1719.56%
- ROE
- 171.72%
- ROIC
- 210.04%
Growth & Income
- Revenue
- $2.20M · 0.00%
- Net Income
- $-37,882,000 · 50.25%
- EPS
- $-7.73 · 64.01%
- Op Income
- $-40,499,000
- FCF YoY
- 61.18%
Performance & Tape
- 52W High
- $0.37
- 52W Low
- $0.37
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.94
- Avg Volume
- 0
Get TickerSpark's AI analysis on SEEL
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 29, 24 | Golembiewski Michael Joseph | other | 417 |
| Jan 12, 24 | Mehra Raj | other | 70,383 |
| Jan 12, 24 | Golembiewski Michael Joseph | other | 24,537 |
| Jan 4, 24 | Pascoe Richard W | other | 1,666 |
| Jan 4, 24 | DALESANDRO MARGARET | other | 1,666 |
| Jan 4, 24 | Lian Brian | other | 1,666 |
| Jan 4, 24 | O'Connor Daniel J. | other | 1,666 |
| Nov 30, 23 | Golembiewski Michael Joseph | buy | 83,000 |
| Dec 1, 23 | Mehra Raj | buy | 75,757 |
| Dec 1, 23 | Mehra Raj | buy | 75,757 |
Our SEEL Coverage
We haven't published any research on SEEL yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SEEL Report →